

# Neoadjuvant chemo response predicts sinonasal SCC outcomes

March 8 2016

---



(HealthDay)—For patients with sinonasal squamous cell carcinoma

(SCC), pathologic response to neoadjuvant chemotherapy is associated with disease progression, according to a study published online March 2 in *Head & Neck*.

Hitoshi Hirakawa, M.D., Ph.D., from the Aichi Cancer Center Hospital in Nagoya, Japan, and colleagues performed surgery on 58 patients with sinonasal SCC, including 43 patients who had received [neoadjuvant chemotherapy](#). The pathological response was classified as grade 0, 1, 2, and 3 (no, slight, moderate, and marked effect, respectively), and the correlation for pathological response with prognosis was examined.

The researchers found that 34.9 percent of cases that received neoadjuvant chemotherapy had grade 2 or 3 response. The effective neoadjuvant chemotherapy group (grades 2 and 3 response) had significantly better overall survival, disease-free survival, locoregional control, and freedom from distant metastasis than the less effective neoadjuvant chemotherapy group (grades 0 and 1) and the non-neoadjuvant chemotherapy group combined.

"Pathological response to neoadjuvant chemotherapy in sinonasal SCC was related to disease prognosis," the authors write.

**More information:** [Abstract](#)  
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: Neoadjuvant chemo response predicts sinonasal SCC outcomes (2016, March 8) retrieved 10 May 2024 from <https://medicalxpress.com/news/2016-03-neoadjuvant-chemo-response-sinonasal-scc.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private
---

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.